Oncocyte Corp Files 8-K: Material Agreements Entered and Terminated
Ticker: IMDX · Form: 8-K · Filed: Aug 9, 2024 · CIK: 1642380
Sentiment: neutral
Topics: material-agreement, termination
TL;DR
Oncocyte Corp signed and terminated material deals on Aug 9th. Details TBD.
AI Summary
On August 9, 2024, Oncocyte Corporation entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The filing does not provide specific details on the nature of these agreements or any associated financial figures.
Why It Matters
This filing indicates significant changes in Oncocyte Corporation's contractual relationships, which could impact its business operations and future strategies.
Risk Assessment
Risk Level: medium — The filing indicates significant corporate actions involving material agreements, but lacks specific details, creating uncertainty.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- August 9, 2024 (date) — Date of earliest event reported
FAQ
What was the nature of the Material Definitive Agreement entered into by Oncocyte Corporation on August 9, 2024?
The filing does not specify the nature of the Material Definitive Agreement entered into on August 9, 2024.
What was the nature of the Material Definitive Agreement terminated by Oncocyte Corporation on August 9, 2024?
The filing does not specify the nature of the Material Definitive Agreement terminated on August 9, 2024.
Are there any financial implications mentioned in the 8-K filing regarding the entered or terminated agreements?
No specific financial figures or implications related to the entered or terminated agreements are detailed in this 8-K filing.
What is Oncocyte Corporation's principal executive office address?
Oncocyte Corporation's principal executive offices are located at 15 Cushing, Irvine, California 92618.
What is Oncocyte Corporation's Standard Industrial Classification code?
Oncocyte Corporation's Standard Industrial Classification code is 2835, for IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Stats: 1,101 words · 4 min read · ~4 pages · Grade level 13.7 · Accepted 2024-08-09 06:37:23
Key Financial Figures
- $7,500,000 — from time to time up to an aggregate of $7,500,000 of shares of the Company's common stock
- $50,000,000 — les Agreement in an aggregate amount of $50,000,000 (the "Prior Program"). Upon termination
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex1-1.htm (EX-1.1) — 282KB
- ex5-1.htm (EX-5.1) — 14KB
- ex5-1_001.jpg (GRAPHIC) — 6KB
- 0001493152-24-030865.txt ( ) — 582KB
- ocx-20240809.xsd (EX-101.SCH) — 3KB
- ocx-20240809_lab.xml (EX-101.LAB) — 33KB
- ocx-20240809_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: August 9, 2024 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer